ストックスクリーナーアプリを入手
12.39
1.72%
0.21
前日終値:
$12.18
開ける：
$12.18
24時間の取引高:
114.10K
Relative Volume:
0.47
時価総額：
$991.06M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.56%
1か月 パフォーマンス:
+12.43%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.79
$12.73
1週間の範囲:
$11.79
$14.04
52週間の値動き範囲:
$8.70
$14.04
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
名前
Bridgebio Oncology Therapeutics Inc
セクター
電話
857 702 0377
住所
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
BBOT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
12.39 | 974.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-09-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc (BBOT) 最新ニュース
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks
BBOT to Participate in Upcoming December Investor Healthcare Conferences - The Manila Times
Oppenheimer Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus
Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq
BBOT Analyst Rating Update: Oppenheimer Lowers Price Target | BB - GuruFocus
Oppenheimer Adjusts BridgeBio Oncology Therapeutics Price Target to $22 From $23, Maintains Outperform Rating - MarketScreener
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
A breakup strategy that’s inspiring clinical candidates for cancer - Chemical & Engineering News
BridgeBio Oncology Therapeutics, Inc.'s (NASDAQ:BBOT) largest shareholders are individual investors who were rewarded as market cap surged US$51m last week - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL) - The Globe and Mail
BridgeBio Oncology Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating - TipRanks
BBOT to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - The Manila Times
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducin - The Manila Times
BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price, news, quote and history - Yahoo! Finance UK
Preclinical Data Presented at the 2025 AACR-NCI-EORTC - GlobeNewswire
BBOT presents preclinical data on KRAS inhibitor BBO-11818 - BioWorld MedTech
Piper Sandler Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
BridgeBio Oncology announces new preclinical data on BBO-11818 study - TipRanks
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Yahoo! Finance Canada
BridgeBio affiliate reports 784,720 BBOT shares via services - Stock Titan
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM) - The Globe and Mail
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Bbot announces poster presentations at the 2025 AACR-NCI-EORTC International Conference - MarketScreener
Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference - TradingView
BBOT Announces Poster Presentations at the 2025 - GlobeNewswire
2 Poster Presentations: BBOT to Present KRAS-targeted preclinical data at AACR-NCI-EORTC Oct 2025 - Stock Titan
BridgeBio Oncology Therapeutics, Inc. (BBOT) environment, social and governance (ESG) ratings - Yahoo
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) Is Up 8.01% – Is It Capable Of A Rally? - stocksregister.com
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform (BBOT:NASDAQ) - Seeking Alpha
Leerink Partners Initiates BridgeBio Oncology Therapeutics at Outperform - MarketScreener
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating - Investing.com India
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com UK
HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Bridgebio Oncology Therapeutics Inc (BBOT) 財務データ
Bridgebio Oncology Therapeutics Inc (BBOT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):